- Universally-patient friendly, meaning formulations that can be used in children and adults alike
- Transport of drugs through blood-brain barrier marks top priority for researchers
- North American legal cannabis market projected at more than $24 billion by 2021
- Global market for pain management, drugs and devices estimated at over $61 billion by 2023
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is a Vancouver-based health sciences company dedicated to research and development of innovative, organic and Nature Identical™ options for preventive and curative therapies for a wide array of devastating medical conditions. Developing what the company believes will be the first U.S. Food and Drug Administration-approved cannabidiol (CBD)-soluble gel product to deliver the therapeutic benefits of CBD directly to the central nervous system (CNS) is a top priority for PreveCeutical Chief Researcher Officer Dr. Harry Parekh, who is based at the University of Queensland, Australia, School of Pharmacy (http://cnw.fm/0r9U3).
Breaking through the blood-brain barrier, which functions as the last line of defense for the body’s most vital organ, is a prime research target, as noted in a May 2017 article published by The Pharmaceutical Journal (http://cnw.fm/Ru6sJ). Delivering life-saving drugs directly to the brain to treat complex brain disorders such as Alzheimer’s, Parkinson’s, epilepsy and depression in a safe and…
More from CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com